NLX-112: a First-in-Class, Dual-Acting, Non-Dopaminergic, Drug Candidate for Treatment of Parkinson’s Disease by Adrian Newman-Tancredi, PhD, DSc Read More Clinical ScienceAdrian Newman-Tancredi, PhD, DScAugust 14, 2023Eight, WPC2023, clinical research, levodopa-induced dyskinesia, serotonin, parkinsonism, 5 HT1A receptor Comments
